Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

2.

Charting the Course: From Young Adult Leukemia Patient to Oncologist.

3.

Screening for prostate cancer: is it time to give up digital rectal examination?

4.

Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care

5.

Charles III, King of Kings, is Cancerous.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot